Phase I Open-labeled Trial of Gemcitabine and Dasatinib in Advanced Solid Tumors.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Dasatinib (Primary) ; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Dec 2011 Planned end date changed from 1 Jan 2012 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 24 Mar 2011 Planned end date changed from 1 Jan 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov